Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression

Molecular Cell

Volumn 51, Issue 1, 2013, Pages 46-56

  Chen, Delin ^a   Kon, Ning ^a   Zhong, Jiayun ^a   Zhang, Pingzhao ^a,b   Yu, Long ^b   Gu, Wei ^a  

^a Columbia University ^*  (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; MESSENGER RNA; MYC PROTEIN; PROTEIN P53; CARRIER PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TRIP12 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN STABILITY; UBIQUITINATION; ANIMAL; APOPTOSIS; CELL LINE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; CELL STRAIN HEK293;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELL LINE; CELL PROLIFERATION; DNA DAMAGE; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF; UBIQUITIN-PROTEIN LIGASES;

EID: 84885409944     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2013.05.006     Document Type: Article

References (44)

1. Andersson A., Ritz C., Lindgren D., Edén P., Lassen C., Heldrup J., Olofsson T., Råde J., Fontes M., Porwit-Macdonald A., et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007, 21:1198-1203.
2. Baudino T.A., McKay C., Pendeville-Samain H., Nilsson J.A., Maclean K.H., White E.L., Davis A.C., Ihle J.N., Cleveland J.L. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002, 16:2530-2543.
3. Chen D., Kon N., Li M., Zhang W., Qin J., Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005, 121:1071-1083.
4. Chen D., Shan J., Zhu W.G., Qin J., Gu W. Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 2010, 464:624-627.
5. Chen D., Yoon J.B., Gu W. Reactivating the ARF-p53 axis in AML cells by targeting ULF. Cell Cycle 2010, 9:2946-2951.
6. Chio I.I., Sasaki M., Ghazarian D., Moreno J., Done S., Ueda T., Inoue S., Chang Y.L., Chen N.J., Mak T.W. TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation. Nat. Cell Biol. 2012, 14:625-633.
7. Dang C.V., O'Donnell K.A., Zeller K.I., Nguyen T., Osthus R.C., Li F. The c-Myc target gene network. Semin. Cancer Biol. 2006, 16:253-264.
8. di Tommaso A., Hagen J., Tompkins V., Muniz V., Dudakovic A., Kitzis A., Ladeveze V., Quelle D.E. Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities. Exp. Cell Res. 2009, 315:1326-1335.
9. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999, 13:2658-2669.
10. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
11. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
12. Itahana K., Clegg H.V., Zhang Y. ARF in the mitochondria: the last frontier?. Cell Cycle 2008, 7:3641-3646.
13. Kajiro M., Tsuchiya M., Kawabe Y., Furumai R., Iwasaki N., Hayashi Y., Katano M., Nakajima Y., Goto N., Watanabe T., et al. The E3 ubiquitin ligase activity of Trip12 is essential for mouse embryogenesis. PLoS ONE 2011, 6:e25871.
14. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91:649-659.
15. Khan S.H., Moritsugu J., Wahl G.M. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc. Natl. Acad. Sci. USA 2000, 97:3266-3271.
16. Kon N., Zhong J., Qiang L., Accili D., Gu W. Inactivation of arf-bp1 induces p53 activation and diabetic phenotypes in mice. J.Biol. Chem. 2012, 287:5102-5111.
17. Kovi R.C., Paliwal S., Pande S., Grossman S.R. An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis. Cell Death Differ. 2010, 17:513-521.
18. Kuo M.L., Duncavage E.J., Mathew R., den Besten W., Pei D., Naeve D., Yamamoto T., Cheng C., Sherr C.J., Roussel M.F. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res. 2003, 63:1046-1053.
19. Kuo M.L., den Besten W., Bertwistle D., Roussel M.F., Sherr C.J. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 2004, 18:1862-1874.
20. Liu J., Levens D. Making myc. Curr. Top. Microbiol. Immunol. 2006, 302:1-32.
21. Lo D., Lu H. Nucleostemin: Another nucleolar "Twister" of the p53-MDM2 loop. Cell Cycle 2010, 9:3227-3232.
22. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
23. Mateyak M.K., Obaya A.J., Adachi S., Sedivy J.M. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 1997, 8:1039-1048.
24. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
25. Murphy D.J., Junttila M.R., Pouyet L., Karnezis A., Shchors K., Bui D.A., Brown-Swigart L., Johnson L., Evan G.I. Distinct thresholds govern Myc's biological output invivo. Cancer Cell 2008, 14:447-457.
26. Naik E., Michalak E.M., Villunger A., Adams J.M., Strasser A. Ultraviolet radiation triggers apoptosis of fibroblasts and skin keratinocytes mainly via the BH3-only protein Noxa. J.Cell Biol. 2007, 176:415-424.
27. Ozenne P., Eymin B., Brambilla E., Gazzeri S. The ARF tumor suppressor: structure, functions and status in cancer. Int. J. Cancer 2010, 127:2239-2247.
28. Pomerantz J., Schreiber-Agus N., Liégeois N.J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.W., et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998, 92:713-723.
29. Rabbitts P.H., Watson J.V., Lamond A., Forster A., Stinson M.A., Evan G., Fischer W., Atherton E., Sheppard R., Rabbitts T.H. Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J. 1985, 4:2009-2015.
30. Ramsay G., Evan G.I., Bishop J.M. The protein encoded by the human proto-oncogene c-myc. Proc. Natl. Acad. Sci. USA 1984, 81:7742-7746.
31. Renneville A., Roumier C., Biggio V., Nibourel O., Boissel N., Fenaux P., Preudhomme C. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008, 22:915-931.
32. Saporita A.J., Maggi L.B., Apicelli A.J., Weber J.D. Therapeutic targets in the ARF tumor suppressor pathway. Curr. Med. Chem. 2007, 14:1815-1827.
33. Sharpless N.E., DePinho R.A. Telomeres, stem cells, senescence, and cancer. J.Clin. Invest. 2004, 113:160-168.
34. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2001, 2:731-737.
35. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 2006, 6:663-673.
36. Tompkins V.S., Hagen J., Frazier A.A., Lushnikova T., Fitzgerald M.P., di Tommaso A., Ladeveze V., Domann F.E., Eischen C.M., Quelle D.E. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. J.Biol. Chem. 2007, 282:1322-1333.
37. Tran P.T., Fan A.C., Bendapudi P.K., Koh S., Komatsubara K., Chen J., Horng G., Bellovin D.I., Giuriato S., Wang C.S., et al. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS ONE 2008, 3:e2125.
38. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 2007, 13:23-31.
39. Vousden K.H., Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:275-283.
40. Zeller K.I., Jegga A.G., Aronow B.J., O'Donnell K.A., Dang C.V. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003, 4:R69.
41. Zeng Y., Kotake Y., Pei X.H., Smith M.D., Xiong Y. p53 binds to and is required for the repression of Arf tumor suppressor by HDAC and polycomb. Cancer Res. 2011, 71:2781-2792.
42. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92:725-734.
43. Zhao Z., Zuber J., Diaz-Flores E., Lintault L., Kogan S.C., Shannon K., Lowe S.W. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 2010, 24:1389-1402.
44. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998, 12:2424-2433.